Brind.

FDA granted Fast Track designation to CELZ-201-DDT, a therapy developed by Creative Medical Technology Holdings for Degenerative Disc Disease.

2 reports, 2 independent Updated Aug 13

Gone quiet Reached 2 outlets in its first 24 hours

Reports: 2
Developments: 2
Repetition: 0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

FDA granted Fast Track designation to CELZ-201-DDT, a therapy developed by Creative Medical Technology Holdings for Degenerative Disc Disease.

Who's involved

What this event is mainly about

FDA

How it developed

Newest first. Tap a step to see who reported it.

Aug 13FDA grants Fast Track designation for DDD therapy CELZ-201-DDT.1 source
- GlobeNewswire
Aug 11Company revenue forecast growth exceeds industry average.1 source
- Simply Wall St.

Keep exploring

The entities involved

FDA
- Dario Amodei warns government leaders about AI risks and calls for strict guardrails on AI development.13:44
- Cognition Therapeutics, Inc. discussed registrational program key aspects with the FDA in May and received Notice of Allowance for a patent application on June 16.12:36

Related events

FDA provided guidance for HCW Biologics' IND application.Fri 15:25

Coverage

Newest first; wire copies grouped

Aug 13GlobeNewswireCreative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT - Advancing Breakthrough Therapy for Chronic Lower Back Pain PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creati
Aug 11Simply Wall St.Creative Medical Technology Holdings Second Quarter 2025 Earnings: US$0.48 loss per share (vs US$1.11 loss in 2Q 2024) Explore Creative Medical Technology Holdings's Fair Values from the Community an